S.A.N.T.E. (Spraying And Nets Towards malaria Elimination)

Today, many partners are concerned with reducing malaria (WHO, National Control Programmes, The Global Fund, etc ) and the current best practice for malaria control is the use of Artemisinin-based combination therapies , e.g. Coartem®, and long-lasting impregnated nets (LLINs) for vector control tool. Many countries are also using indoor residual spraying (IRS) as it […]

Partnership for the Rapid Elimination of Trachoma (PRET)

Trachoma is the leading infectious cause of blindness worldwide and affects millions of people in poor and rural regions. The Partnership for the Rapid Elimination of Trachoma (PRET) is a cluster randomized control trial taking place in three countries: The Gambia, Tanzania and Niger. It aims to answer two main questions: The WHO recommends that […]

TB Biomarkers (Grand Challenge)

Tuberculosis (TB) is a major health problem especially in the developing world. It has been estimated that one third of the global population is latently infected with Mycobacterium tuberculosis. Despite years of effort we currently have no reliable biomarkers for identifying protective immunity against TB and for the various disease states, or for predicting response […]

Pneumococcal Protein Vaccine trial in infants

Pneumococcal disease, primarily bacteraemic pneumonia, is a leading cause of childhood mortality. Pneumococcal conjugate vaccines (PCVs) have enormous potential to reduce the burden of pneumococcal diseases. Currently, three pneumococcal conjugate vaccines containing 7, 10 and 13 pneumococcal serotypes respectively are available for use in infants and toddlers. Despite improved serotype coverage with higher valency conjugate […]

MVA85A tuberculosis Vaccine trial in HIV-infected adults

The available tuberculosis vaccine, BCG, provides incomplete protection against pulmonary tuberculosis. Due to natural inhibition of a second dose, a BCG revaccination does not provide additional protection. MVA85A/AERAS-485 vaccine incorporates a tuberculosis antigen within a live but non-replicating virus vector, which increases specific- T-cell immunity, and thus protection against tuberculosis. MVA85A/AERAS-485 has been administered in […]

M72-TB Vaccine trial in infants

Mycobacterium tuberculosis(Mtb), is responsible for about 9 million new cases of TB and 1.6 million deaths each year. BCG prevents disseminated TB in young children but not primary TB. A study in Cape Town showed that over 3% of infants developed pulmonary TB within 2 year of BCG vaccination (Hawkridge et al., 2008), thus children […]

Pneumococcal Surveillance Project

At the present time there are no data demonstrating the effectiveness of pneumococcal conjugate vaccines (PCV) when used in EPI schedules in Africa. Questions remain regarding the magnitude of the effectiveness of PCV when delivered in a routine EPI, herd protection for unimmunised individuals, serotype replacement, cost-effectiveness, and effectiveness against particular pneumococcal serotypes which are […]

Global Enteric Multicentre Study

The World Health Organization (WHO) ranks diarrheal disease as the second (only after pneumonia) leading cause of mortality among children under five years (60 months) of age in developing countries, accounting for 18% of the 10.6 million children death each year in this age group. It is important to understand and estimate the disease burden, […]